Bifogade filer
Toleranzia AB Interim Report 2023 07 01 – 2023 09 30 ENG
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Three months, July 1 - September 30
· Net sales amounted to -- KSEK (--)
· Profit after financial items amounted to KSEK -1,099 (-2,121).
· Cash flow from operating activities amounted to KSEK 134 (-2,595).
· Investments in intangible assets amounted to KSEK 9,792 (2,350).
· Earnings per share amounted to SEK -0.01 (-0.02).
Nine months, January 1 – September 30
· Net sales amounted to -- KSEK (--)
· Profit after financial items amounted to KSEK -5,549 (6,410)
· Cash flow from operating activities amounted to KSEK -3,309 (-6,689)
· Investments in intangible assets amounted to KSEK 39,583 (22,006)
· Earnings per share amounted to SEK -0.05 (-0.06)
The "Company" or "Toleranzia" refers to Toleranzia AB with organization number 556877-2866.
Significant events in the third quarter of 2023
- GMP manufacturing of TOL2 drug substance for clinical study completed
- Freeze-dried formulation of TOL2 developed
- Regulatory GLP toxicology study of TOL2 initiated
- Rights issue of units consisting of shares and warrants of series TO4 completed, which provided the Company with approximately MSEK 43.4 before issue costs
Significant events after the reporting period
- Thomas Pålsson appointed new CFO
Key financial data
| 2023-07-01 | 2022-07-01 | 2023-01-01 | 2022-01-01 | 2022-01-01 | |
| 2023-09-30 | 2022-09-30 | 2023-09-30 | 2022-09-30 | 2022-12-31 | |
| 3 months | 3 months | 9 months | 9 months | 12 months | |
| Net sales KSEK | - | - | - | - | - |
| Operating profit/loss KSEK | - 1 292 | - 2 137 | - 5 769 | - 6 458 | - 8 639 |
| Profit/loss for the period KSEK | - 1 099 | - 2 121 | - 5 549 | - 6 410 | - 8 456 |
| Total assets KSEK | 163 996 | 125 968 | 163 996 | 125 968 | 125 632 |
| Cash flow for the period KSEK | 31 808 | - 4 945 | - 1 426 | - 28 695 | - 42 341 |
| Cash and bank balances KSEK | 32 511 | 47 583 | 32 511 | 47 583 | 33 937 |
| Equity KSEK | 155 544 | 121 555 | 155 544 | 121 555 | 119 509 |
| Earnings per average share SEK | - 0,01 | - 0,02 | - 0,05 | - 0,06 | - 0,08 |
| Equity/assets ratio (%) | 94,8 | 96,5 | 94,8 | 96,5 | 95,1 |
| Number of shares at the end of the period (no.) | 197 070 875 | 110 315 231 | 197 070 875 | 110 315 231 | 110 315 231 |
| Avarage number of shares (no.) | 114 087 216 | 110 315 231 | 110 370 498 | 110 315 231 | 110 315 231 |
| Number of employees and consultans | 11 | 9 | 11 | 8 | 8 |
Comments from the CEO
Strong value development in the business
It is very satisfying to summarize the third quarter of the year where we have taken major steps forward in the development of the drug candidate TOL2 and strengthened the financial base for continued operations through a rights issue that raised approximately SEK 43.4 before issue costs. Not least, we have initiated the very important GLP toxicology study of TOL2 in the new freeze-dried formulation. In addition, our contract manufacturing partner has completed large-scale manufacturing of the drug substance in its GMP facility.
Optimized drug formulation
Earlier this year, we initiated a formulation development program. This included extensive testing of TOL2 in various compositions, leading to a final freeze-dried drug product with optimized storage, reconstitution and stability properties. We are currently investigating the long-term stability of the product to determine its shelf life. Our expectation is that it will be at least two years, which is very good and fully sufficient for the clinical program.
Safety and tolerability evaluation
The new formulation is now being used in the ongoing GLP toxicology study conducted at Charles River Laboratories in France. The study, which evaluates the safety and tolerability of TOL2 in a preclinical model, represents a very important part of the preclinical documentation required by regulatory authorities when we apply for authorization to initiate our first clinical study in patients with myasthenia gravis. The exposure phase has been completed and the initial observations have not indicated any unwanted effects. Further work focuses on careful examination of tissues and detailed biochemical and immunological analyses. A first preliminary report is expected shortly after the year-end.
Full-scale GMP manufacturing
In early August, we completed the full-scale GMP manufacturing of the drug substance TOL2 together with our contract manufacturing partner. The final quality analyses are now underway and, provided that all specifications are met, the manufacturing will be completed and the drug substance will be ready for final formulation, packaging and labeling into a finished pharmaceutical product with GMP quality. Thereafter, the product will be delivered continuously to the clinical centers involved in the study in patients with myasthenia gravis.
Strengthened financial base
At the end of August, we also carried out a new share issue where we successfully strengthened the cash position by approximately MSEK 43.4 before issue costs. With the improved financial base for the business, we expect to be able to complete the preclinical activities and documentation of TOL2 and take the project towards clinical studies.
Overall, we have achieved several key milestones for the TOL2 project during the quarter. We look forward with confidence to the results from the GLP toxicology study and upcoming interactions with regulatory authorities - two important milestones in the TOL2 development program as they represent the final steps before the submission of the clinical trial application. Recent progress brings us ever closer to our goal - to offer a completely new type of treatment for this rare but serious disease that currently lacks a safe, disease-specific and effective therapy.
Charlotte Fribert
Executive Director
Gothenburg, October 27, 2023
About Toleranzia
General information about the business
Toleranzia AB (556877-2866) is a Swedish biotechnology company listed on Nasdaq First North. The Company develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases (rare diseases). The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's main focus is the autoimmune nerve and muscle disease myasthenia gravis, for which the Company is developing the drug candidate TOL2. In addition, Toleranzia is working on the autoimmune blood vessel disease ANCA-vasculitis, for which the Company is developing the drug candidate TOL3. Both diseases are so-called orphan diseases and there is a great medical need and market potential for both. For further information, please visit: www.toleranzia.com.
Company structure and shareholding
Toleranzia was founded by researchers at the University of Gothenburg. The company operates at the Biotech Center in Gothenburg. Toleranzia has no subsidiaries and is not part of any group. Nor does the company have any shareholdings in other companies.
Financial development and position
Period July - September
Net sales amounted to KSEK -- (--) during the quarter.
Other income amounted to KSEK 213 (71) during the quarter and consists of project grants from Vinnova and foreign exchange gains.
The company's operating expenses amounted to KSEK 11,297 (4,558) for the quarter, of which KSEK 1,214 (1,210) relates to personnel costs.
The increased costs are in line with the Company's plan and expectations linked to the long-term strategy.
Of the total cost, KSEK 9,792 (2,350) relates to the development of the company's project portfolio in myasthenia gravis and ANCA vasculitis, where the costs incurred are capitalized on an ongoing basis as own-account work.
The operating result during the quarter amounted to KSEK -1,292 (-2,137).
The period January – September
Net sales amounted to KSEK – (--) during the period.
Other income amounted to KSEK 261 (72) during the period and consists of project grants from Vinnova and foreign exchange gains.
Operating expenses for the Company amounted to KSEK 45,613 (28,536) during the period, of which KSEK 4,072 (3,646) are costs for personnel.
The costs for the Company's development work represent 87% (77%) of the total operating costs. The cost of development work for the Company's project portfolio in myasthenia gravis and ANCA vasculitis amounted to KSEK 39,583 (22,006). The costs incurred are capitalized on an ongoing basis as own-account work.
Operating profit/loss for the period amounted to KSEK -5,769 (-6,458).
Cash flow and liquidity
For the period July - September, cash flow from operating activities amounted to KSEK 134 (-2,595). For the period January – September cash flow from operating activities amounted to KSEK -3,309 (-6,689).
As of September 30, the Company's cash and bank balance amounted to KSEK 32,511 (47,583).
Investments
Total investments in intangible assets amounted to KSEK 9,792 (2,350) for the period July - September. Total investments in intangible assets amounted to KSEK 39,583 (22,006) for the period January - September.
The investments relate to the development of the Company's project portfolio within myasthenia gravis and ANCA vasculitis and the costs are capitalized on an ongoing basis as own-account work.
Human resources
Toleranzia is a development company where dedicated employees with solid experience and expertise are a prerequisite for commercial success and for achieving the Company's vision. The Company had 11 full-time equivalent employees or contracted consultants as of September 30, 2023.
Financing
During the fall, the company carried out a new share issue that provided the company with capital and liquid funds of approximately MSEK 43.4, before issue costs.
The company has a continuous focus on cash flow. The Board of Directors and management work continuously to ensure long-term and sustainable financing of ongoing and planned development projects and believe that there are several possible alternatives to ensure continued satisfactory financing of the Company.
In light of the above, the report has been prepared on a going concern basis.
Related party transactions
The company has related party transactions regarding the purchase of services in process development for protein production from the company NorthX Biologics Matfors AB, which is partly owned by Flerie Invest AB, whose executive chairman, Thomas Eldered, is a member of Toleranzia's board of directors. Purchased services have been made on market terms.
Ongoing unrest in Europe
There is a general uncertainty in the market caused by the ongoing conflict in Ukraine. The uncertainty has so far not affected the company's operations and is not expected to affect operations in the coming months. Toleranzia has no operations in either the Russian or Ukrainian market. Raw materials and expertise are sourced from neither Russia nor Ukraine.
Shares
Toleranzia's shares are traded on Nasdaq First North Growth Market since October 15, 2020. The number of shares in Toleranzia amounted to 197,070,875 as of September 30, 2023. The share capital amounted to SEK 24,633,859, as of September 30, 2023. The Company has one class of shares, of which each share has a quota value of SEK 0.125 (SEK 0.125) and carries equal rights to participate in the Company's assets and earnings.
There are no ongoing option programs at the time of publication of this interim report.
Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at: ca@mangold.se.
Ownership September 30, 2023
| Shareholder | Share of | Share of |
| capital | Votes | |
| FLERIE INVEST AB | 47,4 % | 47,4 % |
| FÖRSÄKRINGSAKTIEBOLAGET AVANZA PENSION | 3,0 % | 3,0 % |
| S & B CHRISTENSEN AB | 2,0 % | 2,0 % |
| NORDNET PENSIONSFÖRSÄKRING AB | 1,8 % | 1,8 % |
| NORDEA LIVFÖRSÄKRING SVERIGE AB | 1,6 % | 1,6 % |
| NORDIC TENDER AB | 1,4 % | 1,4 % |
| KONSTRUKTIONS O FÖRSÄLJNINGSAKTIEBOLAGET KFAB | 1,1 % | 1,1 % |
| STREMPL, PATRIK | 1,1 % | 1,1 % |
| BERGSTRÖM, NIKLAS TOBIAS | 1,0 % | 1,0 % |
| KAUFMANN, JOHAN | 0,9 % | 0,9 % |
| OTHERS | 38,8 % | 38,8 % |
| Total | 100,0 % | 100,0 % |
Review by the auditor
This interim report has not been reviewed by the Company's auditors.
Financial calendar
Year-end report 2023 2024-02-23
The Board of Directors and the CEO hereby certify that the interim report gives a true and fair view of the Company's operations and financial position.
Gothenburg, October 27, 2023
Toleranzia AB
The Board of Directors and CEO
The English version of the quarterly report is an internal translation. In case of any discrepancies, the Swedish text applies.